Résumé
La famille des cytokines IL-1 (IL-1α, IL-1β, IL-1Ra et, plus récemment, IL-18) joue un rôle important dans la régulation immunitaire et dans les processus inflammatoires en induisant l’expression de nombreuses protéines effectrices ie des cytokines/chemokines, la N0 synthétase, des métalloprotéases (MMP), des Prostaglandines (PGE2). La dérégulation de ces médiateurs peut entraîner une atteinte tissulaire observée dans de nombreuses maladies rhumatismales. Les traitements ciblant l’IL-1 peuvent se révéler efficaces dans ces circonstances (1). Nous parlerons essentiellement de la seule molécule actuellement disponible en France, à savoir l’anakinra, qui est une protéine recombinante, antagoniste du récepteur de l’IL-1 humaine. L’IL-1Ra se he au récepteur actif de l’IL-1 (IL-1R1) sans activer la cellule et donc sans induire lui-même d’effets biologiques, régulant ainsi l’activité de l’IL-1.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
Références
Barksby HE, Lea SR, Preshaw PM, Taylor JJ (2007) The expanding family of interleukin-2. cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 149:217–25
Dayer JM (2003) The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology 2(Suppl): 3–10
Dayer JM (2002) The saga ofthe discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine 69:123–32
van den Berg WB (2001) Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum 30(Suppl): 7–16
Bresnihan B, Alvaro-Gracia JM, Cobby M. et al. (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41:2196–204
Jiang Y, Genant HK, Watt I et al. (2000) A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43:1001–9
Cohen SB, Moreland LW, Gush JJ et al. (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63:1062–8
Gohen S, Hurd E, Gush J et al. (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46: 614–24
Genovese MG, Gohen S, Moreland L et al. (2004) Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50:1412–9
Le Loët X, Nordström D, Rodriguez M. et al. (2008) Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial. J Rheumatol 35:1538–44
Purst DE, Keystone EG, Fleischmann R et al. (2010) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 69(Suppl) 2–29
Salliot G, Dougados M, Gossec L (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68: 25–32
Lequerré T, Bansard G, Derambure G et al (2008) IL-1 gene signature is able to predict the responsiveness to anakinra. American College of Rheumatology, San Francisco, 25-29 octobre. Arthritis Rheum 58(Suppl): 777
Lequerré T, Vittecoq O, Le Loët X (2007) What is the role for interleukin-1 receptor antagonist in rheumatic disease? Joint Bone Spine 74:223–6
Lequerré T, Quartier P, Rosellini D et al. (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67: 302–8
Pascual V, Allantaz F, Arce E et al. (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201:1479–86
Frenkel J, Rijkers GT, Mandey SH et al. (2002) Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D andperiodic fever syndrome. Arthritis Rheum 46: 2794–803
Kalliolias GD, Liossis SN (2008) The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still’s disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 17: 349–59
Burger D, Dayer JM, Palmer G, Gabay G (2006) Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Glin Rheumatol 20: 879–96
Pels E, Sundy JS (2008) Refractory gout: what is it and what to do about it? Gurr Opin Rheumatol 20:198–202
Rights and permissions
Copyright information
© 2011 Springer-Verlag France, Paris
About this chapter
Cite this chapter
Le Loët, X., Lequerré, T., Vittecoq, O. (2011). Les traitements ciblant l’IL-1: quelles maladies?. In: Biothèrapies en rhumatologie. Springer, Paris. https://doi.org/10.1007/978-2-8178-0124-7_9
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0124-7_9
Publisher Name: Springer, Paris
Print ISBN: 978-2-8178-0123-0
Online ISBN: 978-2-8178-0124-7